| Analysis | Metabolite Name | Measured Value | Units | Organ | Cancer status | Smoker | Gender |
|---|---|---|---|---|---|---|---|
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 99 | Peak area | Plasma | NA | NA | NA |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 107 | Peak area | Plasma | NA | NA | NA |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 114 | Peak area | Plasma | NA | NA | NA |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 115 | Peak area | Plasma | NA | NA | NA |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 130 | Peak area | Plasma | NA | NA | NA |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 131 | Peak area | Plasma | Healthy | Current | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 132 | Peak area | Plasma | Adenocarcinoma | Current | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 139 | Peak area | Serum | Adenocarcinoma | Current | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 141 | Peak area | Serum | Adenocarcnoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 147 | Peak area | Plasma | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 147 | Peak area | Plasma | NA | NA | NA |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 150 | Peak area | Plasma | NA | NA | NA |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 160 | Peak area | Plasma | Healthy | Current | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 162 | Peak area | Plasma | Adenocarcinoma | Current | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 165 | Peak area | Plasma | NA | NA | NA |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 165 | Peak area | Serum | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 167 | Peak area | Plasma | Adenocarcinoma | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 169 | Peak area | Serum | Healthy | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 173 | Peak area | Plasma | Adenocarcinoma | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 175 | Peak area | Plasma | NA | NA | NA |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 176 | Peak area | Plasma | NA | NA | NA |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 177 | Peak area | Plasma | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 177 | Peak area | Serum | Healthy | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 178 | Peak area | Plasma | Healthy | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 178 | Peak area | Plasma | NA | NA | NA |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 181 | Peak area | Plasma | NA | NA | NA |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 183 | Peak area | Plasma | Healthy | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 183 | Peak area | Serum | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 187 | Peak area | Plasma | NA | NA | NA |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 192 | Peak area | Plasma | Healthy | Current | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 192 | Peak area | Plasma | Healthy | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 192 | Peak area | Serum | Healthy | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 193 | Peak area | Plasma | NA | NA | NA |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 197 | Peak area | Plasma | Healthy | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 197 | Peak area | Plasma | Healthy | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 200 | Peak area | Plasma | Adenocarcinoma | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 203 | Peak area | Serum | Healthy | Current | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 206 | Peak area | Serum | Adenocarcinoma | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 212 | Peak area | Plasma | NA | NA | NA |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 218 | Peak area | Serum | Healthy | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 219 | Peak area | Serum | Adenocarcinoma | Current | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 222 | Peak area | Serum | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 225 | Peak area | Plasma | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 226 | Peak area | Plasma | NA | NA | NA |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 227 | Peak area | Plasma | NA | NA | NA |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 231 | Peak area | Plasma | Healthy | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 237 | Peak area | Plasma | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 239 | Peak area | Plasma | Adenocarcinoma | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 242 | Peak area | Serum | Adenocarcnoma | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 247 | Peak area | Plasma | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 253 | Peak area | Plasma | Adenocarcinoma | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 255 | Peak area | Serum | Healthy | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 256 | Peak area | Plasma | Adenocarcnoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 258 | Peak area | Serum | Adenocarcinoma | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 261 | Peak area | Serum | Adenosquamous | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 262 | Peak area | Plasma | Adenocarcinoma | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 269 | Peak area | Plasma | Healthy | Current | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 270 | Peak area | Plasma | Healthy | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 273 | Peak area | Serum | Adenocarcinoma | Current | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 273 | Peak area | Serum | Healthy | Current | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 280 | Peak area | Serum | Healthy | Current | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 285 | Peak area | Serum | Healthy | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 289 | Peak area | Plasma | Healthy | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 290 | Peak area | Serum | Healthy | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 292 | Peak area | Serum | Healthy | Current | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 293 | Peak area | Plasma | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 294 | Peak area | Plasma | Adenocarcinoma | Current | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 294 | Peak area | Serum | Healthy | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 295 | Peak area | Serum | Adenocarcinoma | Current | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 295 | Peak area | Serum | Adenocarcinoma | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 299 | Peak area | Serum | Adenocarcinoma | Current | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 301 | Peak area | Plasma | Adenocarcinoma | Current | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 303 | Peak area | Serum | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 307 | Peak area | Serum | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 312 | Peak area | Plasma | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 329 | Peak area | Plasma | Healthy | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 329 | Peak area | Serum | Healthy | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 329 | Peak area | Serum | Healthy | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 332 | Peak area | Serum | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 336 | Peak area | Serum | Adenocarcinoma | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 342 | Peak area | Serum | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 347 | Peak area | Serum | Adenosquamous | Current | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 348 | Peak area | Serum | Healthy | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 351 | Peak area | Serum | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 353 | Peak area | Serum | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 354 | Peak area | Plasma | NA | NA | NA |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 359 | Peak area | Plasma | Adenocarcinoma | Current | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 359 | Peak area | Plasma | Healthy | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 363 | Peak area | Serum | Healthy | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 366 | Peak area | Plasma | Healthy | Current | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 366 | Peak area | Serum | Adenocarcinoma | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 367 | Peak area | Plasma | Adenosquamous | Current | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 370 | Peak area | Plasma | Healthy | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 372 | Peak area | Plasma | Adenocarcinoma | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 379 | Peak area | Serum | Adenocarcinoma | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 389 | Peak area | Serum | Healthy | Current | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 392 | Peak area | Plasma | Healthy | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 394 | Peak area | Plasma | Healthy | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 396 | Peak area | Serum | Healthy | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 397 | Peak area | Plasma | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 398 | Peak area | Serum | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 400 | Peak area | Plasma | Adenocarcinoma | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 408 | Peak area | Plasma | Adenosquamous | Current | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 412 | Peak area | Plasma | Adenocarcinoma | Current | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 420 | Peak area | Serum | Healthy | Current | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 427 | Peak area | Serum | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 428 | Peak area | Plasma | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 431 | Peak area | Plasma | Healthy | Current | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 433 | Peak area | Serum | Healthy | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 439 | Peak area | Plasma | Healthy | Current | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 447 | Peak area | Serum | Healthy | Current | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 449 | Peak area | Plasma | Healthy | Current | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 450 | Peak area | Plasma | Healthy | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 452 | Peak area | Plasma | Healthy | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 456 | Peak area | Serum | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 457 | Peak area | Plasma | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 459 | Peak area | Serum | Adenocarcinoma | Current | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 460 | Peak area | Plasma | Healthy | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 462 | Peak area | Serum | Adenocarcinoma | Current | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 467 | Peak area | Plasma | Adenosquamous | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 472 | Peak area | Plasma | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 478 | Peak area | Plasma | Healthy | Current | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 483 | Peak area | Plasma | Healthy | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 484 | Peak area | Plasma | Adenocarcinoma | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 485 | Peak area | Serum | Adenocarcnoma | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 486 | Peak area | Serum | Adenosquamous | Current | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 487 | Peak area | Serum | Healthy | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 491 | Peak area | Serum | Healthy | Current | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 507 | Peak area | Serum | Healthy | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 526 | Peak area | Serum | Healthy | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 528 | Peak area | Serum | Adenocarcinoma | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 550 | Peak area | Serum | Adenocarcinoma | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 554 | Peak area | Plasma | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 562 | Peak area | Plasma | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 564 | Peak area | Plasma | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 566 | Peak area | Plasma | Adenocarcinoma | Current | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 566 | Peak area | Serum | Adenocarcinoma | Current | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 570 | Peak area | Serum | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 575 | Peak area | Plasma | Adenocarcinoma | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 579 | Peak area | Plasma | Adenocarcinoma | Current | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 588 | Peak area | Plasma | Healthy | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 596 | Peak area | Plasma | Adenocarcinoma | Current | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 604 | Peak area | Plasma | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 605 | Peak area | Plasma | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 607 | Peak area | Plasma | Adenocarcnoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 656 | Peak area | Plasma | Adenocarcinoma | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 670 | Peak area | Serum | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 689 | Peak area | Serum | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 706 | Peak area | Serum | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 708 | Peak area | Plasma | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 713 | Peak area | Serum | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 723 | Peak area | Serum | Healthy | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 750 | Peak area | Plasma | Adenocarcnoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 796 | Peak area | Serum | Healthy | Current | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 812 | Peak area | Plasma | Adenocarcinoma | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 826 | Peak area | Serum | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 908 | Peak area | Plasma | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 915 | Peak area | Plasma | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 989 | Peak area | Plasma | Healthy | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 1048 | Peak area | Plasma | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 1058 | Peak area | Serum | Healthy | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 1145 | Peak area | Serum | Adenocarcinoma | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 1210 | Peak area | Serum | Adenocarcinoma | Current | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 1383 | Peak area | Plasma | Healthy | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 1402 | Peak area | Serum | Adenocarcinoma | Former | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 1769 | Peak area | Serum | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 2226 | Peak area | Plasma | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 2488 | Peak area | Plasma | Adenocarcinoma | Current | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 2687 | Peak area | Serum | Healthy | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 4173 | Peak area | Serum | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 6890 | Peak area | Serum | Adenocarcinoma | Current | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 12351 | Peak area | Plasma | Healthy | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 13125 | Peak area | Serum | Healthy | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 13545 | Peak area | Serum | Adenocarcinoma | Former | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 15259 | Peak area | Plasma | Adenocarcinoma | Current | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 15451 | Peak area | Plasma | Adenocarcinoma | Current | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 16508 | Peak area | Serum | Adenocarcinoma | Current | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 22450 | Peak area | Plasma | Healthy | Current | F |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 23690 | Peak area | Serum | Adenocarcinoma | Current | M |
| GC POSITIVE ION MODE | butane-2,3-diol (NIST) | 57446 | Peak area | Serum | Healthy | Current | F |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|